Skip to content

LBRX LBRX Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.2×-0.6×
Alkermes logo
AlkermesALKS
0.9×+0.9×
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
Alto Neuroscience logo
Alto NeuroscienceANRO
0.1×-0.1×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-1.5×
Opko Health logo
Opko HealthOPK
0.0×

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Current ratio35.7×

Where this comes from

Calculated from LBRX’s reported figures.

Based on the most recent quarter.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's debt-to-equity?
LBRX (LBRX) reported debt-to-equity of 0× in Q1 2026.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.